MorphoSys and Heptares to develop antibody therapeutics targeting GPCRs

Published: 13-Feb-2013
Research & Development Pharmaceutical

MorphoSys will apply Ylanthia library to develop products against StaRs from Heptares


MorphoSys has signed an agreement with Heptares Therapeutics, a UK-based GPCR drug discovery and development company, to discover antibody therapeutics targeting G protein-coupled receptors (GPCRs), the membrane proteins involved in a range of biological processes and diseases.

Under the terms of the agreement, Heptares will generate stabilised receptors (StaRs) for a set of GPCR disease targets proposed by MorphoSys. MorphoSys will then apply its Ylanthia antibody library to discover and develop antibody therapeutics against these StaRs.

MorphoSys has the right to sub-license access to these targets in conjunction with therapeutic antibody candidates. Heptares will receive upfront and research funding payments, plus a share of future sublicensing revenues generated by MorphoSys.

Heptares will also use the Ylanthia library to develop and commercialise a therapeutic antibody created by MorphoSys against a GPCR target selected by Heptares. In this case, MorphoSys would receive licensing fees, milestones and royalties on any Ylanthia antibody developed by Heptares.

No financial details have been revealed.

  • Companies:
  • MorphoSys AG
  • Heptares Therapeutics
See more

You may also like

Media

Heptares enters drug collaboration with Imperial

Read more
Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Media

Heptares enters drug collaboration with Imperial

Heptares, the wholly-owned subsidiary of Sosei Group Corporation, has entered a new drug research and development collaboration with Imperial College London
Research & Development

Heptares enters research and drug discovery collaboration

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, launched a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan
Research & Development

New programme focused on GPCR target implicated in brain cancer 

Heptares Therapeutics announced the launch of a new research collaboration under its ORBIT initiative with New York University School of Medicine
Research & Development

Heptares plans relocation to Cambridge, UK

Heptares is planning to create a state of the art research and development facility on Granta Park to support its growth strategy
Research & Development

New insights to advance drug discovery in pain, cancer and inflammation

Heptares collaboration with AstraZeneca yields novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules
Pharmaceutical

Heptares scientists solve structure of CCR9 chemokine receptor offering unique opportunity to apply structure-based design across chemokine receptor family

Chemokine receptor family plays key role across multiple disease areas and represents an important target for drug discovery and development
Ingredients

Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastrointestinal disorders

Sosei Group announces that its subsidiaries, Heptares and Jitsubo Co., Ltd, and have entered into a collaboration to develop novel peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastrointestinal (GI) disorders
Subscribe now